Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Journal of Obesity & Weight Loss Therapy received 2297 citations as per Google Scholar report
Farid Saad
ScientificTracks Abstracts: J Obes Weight Loss Ther
Adipose tissue produces substances that suppress testosterone production. Low testosterone leads to further accumulation of fat
mass. This situation represents a vicious circle. In an ongoing registry study of 347 hypogonadal men (total testosterone ≤12.1
nmol/L and presence of hypogonadal symptoms) being treated with testosterone in a urology office in Germany, only 7.5% had
normal weight (BMI <25 kg/m2) at baseline, 22.8% were overweight (BMI 25-29.9 kg/m2) and 69.8% obese (BMI ≥30 kg/m2). The
same applies to waist circumference (WC): 4.3% with WC<94, 30.8% 94-101.9, and 64.8% ≥102 cm at baseline. This distribution
seems representative for hypogonadal populations. Only when long-term studies (5 years) with injectable testosterone undecanoate
(TU) appeared in 2013 and 2014, substantial and sustained weight loss became apparent. In a controlled study, 5-year treatment
with TU in men with metabolic syndrome resulted in progressive weight loss of 15.4 kg and decrease in WC of 9.6 cm. In registry
studies, patients lost weight in the same magnitude. In none of these studies, patients regained weight during the observation time.
In a meta-analysis on TU, the magnitude of effects depends on baseline BMI, duration of treatment, and age. It can be hypothesized
that increase in lean mass and behavioural changes are factors in achieving weight loss by testosterone treatment. In conclusion,
testosterone may have the potential to decrease obesity in hypogonadal men in a meaningful and sustainable manner.
Farid Saad worked for various Pharmaceutical companies as specialist for reproductive endocrinology, pediatric endocrinology, andrology, endocrinology of male ageing,
and hormonal male contraception in clinical development andrology, scientific and medical affairs. He currently works for Bayer Pharma in Berlin, Germany. He has authored
and co-authored more than 100 peer-reviewed papers and more than 500 scientific abstracts. He received honorary Professorships in clinical research and endocrinology
at Gulf Medical University, Ajman, UAE, and at Men’s Health Reproduction Study Center, Hang Tuah University, Surabaya, Indonesia.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals